The mean disease-free survival was 39.0 months in ALK IHC-negative patients versus 26.3 months in ALK IHC-positive patients (P = 0.001), and the tumor recurrence rate was significantly higher in the ALK IHC-positive group (59.5% vs 35.4%, respectively; P = 0.003). This evidence concerns the gene ALK and neoplasm.